Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
Lunit and 10x Genomics (TXG) are collaborating to integrate Lunit's AI-enabled H&E pathology analysis with 10x Genomics' spatial molecular technologies for oncology clinical research. Lunit SCOPE IO will be incorporated into 10x's oncology biomarker discovery workflow to analyze Hematoxylin and Eosin pathology images alongside spatial molecular data from 10x's Xenium and Atera platforms.
The combined approach is intended to help researchers relate tissue morphology to tumor biology and identify biomarkers linked to treatment response and resistance. Initial work will support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction, as part of 10x's broader effort to explore potential future diagnostic applications of spatial technologies in oncology. Lunit SCOPE IO, which is for research use only, characterizes tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other tumor microenvironment features to complement molecular profiling.
10x Genomics (Nasdaq: TXG) reported that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are licensed from Roche Sequencing Solutions. The jury upheld all three patents as valid and enforceable and awarded 10x Genomics over $4.8 million in damages, based on a 14% royalty rate on Parse’s U.S. sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026. According to 10x Genomics, it will seek enhanced damages, attorneys’ fees, and a permanent U.S. injunction against further infringement in post-trial proceedings.
10x Genomics (Nasdaq: TXG) reported second quarter 2026 revenue of $151.0 million, down from $172.9 million a year earlier. Excluding non-recurring patent litigation settlement revenue in both periods, revenue rose 3% to $149.4 million. Gross margin improved to 74% from 72%, helped by lower manufacturing costs, $2.6 million of tariff refunds and reduced inventory write-downs.
Operating expenses increased to $132.1 million, driven by a much smaller gain on settlement ($3.4 million versus $40.7 million in Q2 2025), resulting in an operating loss of $19.6 million and net loss of $17.9 million. According to 10x Genomics, products and services revenue grew to $149.1 million, while license and royalty revenue fell sharply to $1.9 million. The company ended June 30, 2026 with $552.0 million in cash, cash equivalents and marketable securities, raised its 2026 revenue guidance to $610–$630 million, completed the acquisition of Proteintech Genomics, and announced new multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital.
10x Genomics (Nasdaq: TXG) announced a multi-year research collaboration with Lausanne University Hospital (CHUV) to advance diagnostic applications of single cell and spatial technologies in cancer care. The study will use 10x’s Flex Apex and Xenium platforms, with plans to expand to Atera, on tumor samples from patients with advanced cancers evaluated by a clinical molecular tumor board.
The collaboration aims to identify clinically relevant biomarkers that may help predict treatment response and cancer prognosis across multiple solid tumors, including non-small cell lung, breast, bladder cancer and melanoma, and to explore how 10x technologies could complement current standard-of-care clinical assays.
10x Genomics (Nasdaq: TXG) will report its second quarter 2026 financial results for the period ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook, with materials and the news release available on the investor section of its website and a webcast replay accessible for at least 45 days.
IQM Quantum Computers appointed Craig Ciesla, former 10x Genomics (Nasdaq: TXG) VP of Engineering, as Chief Technology Officer and Inés de Vega as Chief Scientist.
The company is preparing for a planned Nasdaq listing via merger with Real Asset Acquisition Corp (Nasdaq: RAAQ), supported by an upsized $146 million PIPE. IQM operates a vertically integrated quantum computing business and has sold 23 quantum computers to date.
10x Genomics (Nasdaq: TXG) announced a multi-year research collaboration with Cleveland Clinic to advance diagnostic applications for bladder cancer. The partners will use 10x's Flex Apex, Xenium and later Atera platforms to study advanced bladder cancer tumor samples.
The project aims to identify clinically relevant biomarkers predicting response to antibody-drug conjugates and immunotherapies by integrating single cell transcriptomics, spatial gene expression and protein measurements with clinical outcomes.
10x Genomics (Nasdaq: TXG) acquired Proteintech Genomics, a division of Proteintech Group, to expand its single cell and spatial proteomics capabilities. Proteintech Genomics offers differentiated technologies such as the Human Discovery Panel, the largest antibody-based single cell protein panel, designed for integrated RNA and protein analysis within 10x-compatible workflows.
The acquisition supports 10x Genomics' multiomic strategy across its single cell, spatial and Atera platforms. Proteintech Genomics' panels are purpose-built for 10x workflows and already used to measure RNA and protein together. Transaction terms were not disclosed, and TXG expects no meaningful near-term financial impact.
10x Genomics (Nasdaq: TXG) reported Q1 2026 revenue of $150.8 million, a 3% decrease year-over-year; excluding a $16.8 million 2025 one-time patent settlement, revenue rose 9%. Gross margin was 70%. Operating loss was $17.0 million and net loss $13.5 million. Cash and marketable securities totaled $539.8 million, up $112.9 million year-over-year. The company launched Atera, expects shipments in H2 2026, announced a Bioptimus partnership for the STELA initiative, and reaffirmed full-year 2026 revenue guidance of $600–$625 million.
10x Genomics (Nasdaq: TXG) said its management team will take part in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 5:00 p.m. Pacific Time.
The event will be webcast live via the Investors section of the company website and archived for replay for at least 30 days.